Bilcare clarifies director roles after failed executive appointments
- Special resolutions for Executive Director appointments failed at the 39th AGM
- Mohan Bhandari remains Non-Executive Non-Independent Director and CEO
- Kavita Bhansali continues as Non-Executive Non-Independent Director
- Clarification issued to BSE on October 15, 2026

*this image is generated using AI for illustrative purposes only.
Bilcare Ltd clarified that Mohan Bhandari and Kavita Bhansali continue as Non-Executive Non-Independent Directors following the failure of special resolutions to appoint them as Executive Directors at the annual general meeting.
The company stated that Bhandari retains his role as CEO alongside his directorship, while Bhansali continues solely as a Non-Executive Non-Independent Director. This clarification follows a board meeting held on August 13, 2026, which had initially proposed these appointments.
Resolution outcome
During the 39th Annual General Meeting held on September 26, 2026, shareholders did not pass the requisite majority required for the special resolutions. Consequently, the proposed change in designation from Non-Executive to Executive Director status was not implemented for either individual.
| Director | Current Designation | Proposed Designation (Failed) |
|---|---|---|
| Mohan Bhandari | Non-Executive Non-Independent Director & CEO | Executive Director |
| Kavita Bhansali | Non-Executive Non-Independent Director | Executive Director |
The company notified the Bombay Stock Exchange under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure confirms that the initial changes reflected on the BSE portal were provisional pending shareholder approval, which was not secured.
Historical Stock Returns for Bilcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.42% | -3.27% | -1.37% | +43.88% | +43.88% | +43.88% |
Will Bilcare Ltd seek shareholder approval for executive director appointments again at the next general meeting?
How might the rejection of these resolutions impact investor confidence in Bilcare's corporate governance standards?
What are the potential implications for Bilcare's operational strategy given the continued separation of CEO and Executive Director roles?


































